Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 3Completed 2Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Leukemia, Myeloid, Acute 78Leukemia, Lymphocytic, Chronic, B-Cell 77Leukemia 77Myelodysplastic Syndromes 61Lymphoma 51Precursor Cell Lymphoblastic Leukemia-Lymphoma 47Multiple Myeloma 46Lymphoma, Non-Hodgkin 45Hodgkin Disease 36Leukemia, Myelogenous, Chronic, BCR-ABL Positive 31Hematologic Neoplasms 27Melanoma 26Recurrence 20Lymphoma, Follicular 18Lymphoma, Mantle-Cell 17Myeloproliferative Disorders 16Graft vs Host Disease 15Primary Myelofibrosis 14Lymphoma, Large B-Cell, Diffuse 14Lymphoma, B-Cell 13Neoplasms, Plasma Cell 12Lymphoma, B-Cell, Marginal Zone 11Leukemia, Myelomonocytic, Chronic 10Anemia, Aplastic 10Neoplasms 9Hematologic Diseases 9Neoplasm Metastasis 8Blast Crisis 8Anemia, Refractory, with Excess of Blasts 8Ovarian Neoplasms 7

Interventions

Fluorouracil 128Leucovorin 120Oxaliplatin 101Irinotecan 89Bevacizumab 55Cetuximab 44Capecitabine 40Folfox protocol 29Panitumumab 22Colonoscopy 17Chemotherapy, Adjuvant 16Floxuridine 15Early Intervention, Educational 15Erlotinib Hydrochloride 13Surveys and Questionnaires 11IFL protocol 11Counseling 11Celecoxib 11Immunohistochemistry 10Gemcitabine 10Psychiatric Rehabilitation 9Methods 8Magnetic Resonance Spectroscopy 8Gene Expression Profiling 8Exercise 8Dexamethasone 8sargramostim 7Sorafenib 7Radiotherapy 7Nivolumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Colonic Neoplasms × fludarabine × Clear all
NCT04426669 2026-02-23

A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering

Intima Bioscience, Inc.

Phase 1/2 Completed
23 enrolled
Gastrointestinal

Colonic Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

NCT05040568 2026-01-26

A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD)

M.D. Anderson Cancer Center

Phase 1 Completed
15 enrolled
Gastrointestinal

Colonic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡